The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis.
- Author:
Kazuhide INAGE
1
;
Sumihisa ORITA
;
Kazuyo YAMAUCHI
;
Yoshihiro SAKUMA
;
Go KUBOTA
;
Yasuhiro OIKAWA
;
Takeshi SAINOH
;
Jun SATO
;
Kazuki FUJIMOTO
;
Yasuhiro SHIGA
;
Kazuhisa TAKAHASHI
;
Seiji OHTORI
Author Information
- Publication Type:Original Article
- Keywords: Tartrate-resistant acid phosphatase; Receptor activator of nuclear factor-kappa B ligand
- MeSH: Acid Phosphatase; Bone Resorption; Collagen Type I; Compliance*; Humans; Metabolism; Osteogenesis; Osteoporosis*; Patient Dropouts; RANK Ligand; Retrospective Studies
- From:Asian Spine Journal 2015;9(3):338-343
- CountryRepublic of Korea
- Language:English
- Abstract: STUDY DESIGN: Retrospective study. PURPOSE: We conducted a study to investigate the time course changes in bone metabolic markers after the administration of the anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody and to assess drug compliance among osteoporotic patients. OVERVIEW OF LITERATURE: The anti-RANKL antibody is expected to provide an improvement in those with a bone metabolism disorder. However there are only a few clinical reports available on the effect of treatment. METHODS: We included 40 post-menopausal osteoporotic patients who received the anti-RANKL antibody. To determine the time course changes in the bone metabolic markers, we measured the serum tartrate-resistant acid phosphatase 5b (TRACP 5b; a bone resorption marker) and the serum N-terminal propeptide of type 1 collagen (P1NP; a bone formation marker) levels prior to and 1 month after administrating the anti-RANKL antibody. To evaluable drug compliance, we assessed the dropout rate during treatment and at 6 months after treatment. RESULTS: The average TRACP 5b level significantly decreased from 574.8 mU/dL before treatment to 153.2 mU/dL 1 month after treatment (p<0.05). There was no significant difference in the average P1NP level, which was 56.9 microG/L and 35.1 microG/L before and 1 month after treatment, respectively (p>0.05). As for drug compliance, we did not have any dropouts during the treatment or after 6 months (dropout rate: 0%). CONCLUSIONS: Our study suggests that anti-RANKL antibody treatment suppresses bone resorption and maintains bone formation.
